Dexamethasone for the Treatment of Depression: A Randomized, Placebo-Controlled, Double-Blind Trial

George W. Arana, Alberto B. Santos, Michele T. Laraia, Stephen McLeod-Bryant, Mark D. Beale, Laura J. Rames, John M. Roberts, James K. Dias, Monica Molloy

Research output: Contribution to journalArticle

88 Scopus citations

Abstract

Objective: The authors' goal was to assess dexamethasone for the treatment of depression. Method: Thirty-seven outpatients (11 men and 26 women) meeting DSM-III-R criteria for major depressive disorder were randomly assigned to receive either placebo or 4 mg/day of oral dexamethasone for 4 days. Baseline Hamilton depression scale scores were compared with scores obtained 14 days after the first dose of study medication. Data were analyzed by using two-sample t tests, chi-square methods, and Fisher's exact test. Results: Seven (37%) of the 19 patients given dexamethasone but only one (6%) of the 18 patients given placebo responded positively. No adverse events or side effects were reported, and all patients who entered the study completed it. Conclusions: A brief course of oral dexamethasone (4 days) was significantly more effective than placebo within 14 days for the treatment of depression in a randomized, double-blind study of depressed outpatients.

Original languageEnglish (US)
Pages (from-to)265-267
Number of pages3
JournalAmerican Journal of Psychiatry
Volume152
Issue number2
DOIs
StatePublished - Feb 1995
Externally publishedYes

    Fingerprint

ASJC Scopus subject areas

  • Psychiatry and Mental health

Cite this

Arana, G. W., Santos, A. B., Laraia, M. T., McLeod-Bryant, S., Beale, M. D., Rames, L. J., Roberts, J. M., Dias, J. K., & Molloy, M. (1995). Dexamethasone for the Treatment of Depression: A Randomized, Placebo-Controlled, Double-Blind Trial. American Journal of Psychiatry, 152(2), 265-267. https://doi.org/10.1176/ajp.152.2.265